NCT00229736View on ClinicalTrials.gov

A Study of AAV-hAADC-2 in Subjects With Parkinson's Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

November 30, 2004

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions
Parkinson's Disease
Interventions
GENETIC

AAV-hAADC-2

9 x 10\^10 vector genomes (vg) of AAV-hAADC-2 in a single dose of 200 µL bilaterally infused over 4 striatal targets

GENETIC

AAV-hAADC-2

3 x 10\^11 vector genomes (vg) of AAV-hAADC-2 in a single dose of 200 µL bilaterally infused over 4 striatal targets

Trial Locations (1)

Unknown

University of California, San Francisco, San Francisco

All Listed Sponsors
lead

Genzyme, a Sanofi Company

INDUSTRY

NCT00229736 - A Study of AAV-hAADC-2 in Subjects With Parkinson's Disease | Biotech Hunter | Biotech Hunter